Navigation Links
Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
Date:5/8/2012

LOS ANGELES, May 8, 2012 /PRNewswire/ -- Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.  Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores.  Both scales achieved statistical significance.  In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests.  eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

The 11-subject study was conducted at the University of California, Los Angeles (UCLA).  A previous initial report of the first five subjects also found positive results.  "These findings confirm our preliminary observations that eTNS can impact symptoms in pharmacoresistant major depression.  The participants in the study told us that it was easy to use at home, and most noticed that they were feeling substantially better within the first two weeks, with even more improvement in the subsequent weeks.  As a result of these findings, a Phase II clinical trial, to test this potential adjunctive therapy under double-blind conditions, is being conducted at UCLA with funding provided by NeuroSigma.  I'm confident that the transfer of the technology from academia to industry will continue to proceed smoothly and hope this treatment will be made available to many patients in the near future," Dr. Cook said.

This Phase Ib study was an open-label clinical trial of eTNS™ therapy in adults with non-psychotic unipolar MDD that had lasted more than 4 months and had not responded to at least one antidepressant, with a median of 4 medication failures.  Clinical improvements were consistently found across several different ways to measure symptom burden.  

The TNS technology, including eTNS™ for the treatment of depression, was invented and originally developed at UCLA.  NeuroSigma, Inc., a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, is the exclusive worldwide licensee of UCLA's TNS intellectual property.  "We are extremely pleased to be working closely with Dr. Cook and his talented and dedicated team at UCLA," said Dr. Leon Ekchian, President and CEO of NeuroSigma.  "We look forward to helping make his vision of a safe, non-invasive, non-pharmacological therapy for depression available to patients worldwide."

NeuroSigma has completed development of its external TNS (eTNS™) system and is developing its implantable subcutaneous TNS (sTNS™) system.  Once approved by regulatory agencies, patients who respond well to eTNS™ can opt to switch to the implantable sTNS™ system.  Near term milestones include filing a CE Mark application in mid-2012 for approval to commence marketing the eTNS system for the treatment of epilepsy and depression in Europe, and in the second-half of 2012, NeuroSigma is planning to file an IDE with the FDA for a multi-center epilepsy Phase III pivotal trial in the United States. 

Background – TNS

NeuroSigma's eTNS™ system is a non-invasive therapy, which utilizes a self-adhesive conductive pad applied to the forehead to stimulate branches of the trigeminal nerve, which are located very close to the surface of the skin of the forehead.  The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain.  In clinical studies, eTNS™ is well tolerated and the low-energy stimulus is confined to the soft tissues of the face without penetration into the brain.  The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD and other disorders.  PET imaging studies in humans confirm that eTNS™ modulates activity in key regions implicated in these disorders and the changes were observed within minutes of therapy.

CAUTION: Both eTNS™ and sTNS™ systems are investigational devices and at this time are limited by Federal (or United States) law to investigational use.

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice.  Currently, NeuroSigma is focused on a number of neuromodulation therapies and, through its majority-owned subsidiary, NSVascular, Inc., on Thin-Film Nitinol covered stents for endovascular applications.  NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD) via TNS and for PTSD, obesity and cachexia via DBS.  For more information about NeuroSigma, please visit http://www.neurosigma.com.

 


'/>"/>
SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PDI, Inc. to Hold First Quarter 2012 Financial Results Conference Call on Tuesday, May 15, 2012
2. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
3. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
4. Par Pharmaceutical Companies Reports First Quarter 2012 Results
5. InspireMD Announces First Quarter 2012 Financial Results
6. Stereotaxis Reports Improved First Quarter 2012 Financial Results
7. Henry Schein Reports Record First Quarter Results
8. Isis Reports Financial Results and Highlights for First Quarter 2012
9. Insmed Announces First Quarter 2012 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2012 Results
11. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - Medical ... Devices sector report, "Aesthetic Devices - Medical Devices Pipeline ... in pipeline stage. This report is ... primary research by GlobalData,s team of industry experts. ... or altered based on the availability and relevance of ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016  Otsuka Pharmaceutical ... announced that they have entered into a licensing agreement ... in the U.S. and Puerto Rico ... a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new ... --> In a Phase II clinical ...
(Date:2/8/2016)... 2016  Echo Therapeutics, Inc. (Nasdaq: ... on non-invasive continuous glucose monitoring (CGM) and ... it will host a webcast and conference ... 9:00 a.m. Eastern Time to provide a ... advancements in its CGM system, and its ...
Breaking Medicine Technology:
(Date:2/9/2016)... , ... February 09, 2016 , ... ... helping businesses recover after a disaster, announced today the acquisition of Hawaii DKI. ... Hawaii. , “Investing in like-minded companies who excel at service and ...
(Date:2/9/2016)... Cambridge, MA (PRWEB) , ... February 09, 2016 ... ... Institute (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for ... medical services covered in the report, Evaluation of the 2015 Fee Schedule ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... 10, 2016 , ... The Journal of Pain Research has published ... .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet little ... chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
Breaking Medicine News(10 mins):